An integrated multi-study analysis of serum HAI antibody responses to Ann Arbor strain live attenuated influenza vaccine in children and adults  by Coelingh, Kathleen L. et al.
Trials in Vaccinology 3 (2014) 150–153Contents lists available at ScienceDirect
Trials in Vaccinology
journal homepage: www.elsevier .com/locate / t r ivacAn integrated multi-study analysis of serum HAI antibody responses to
Ann Arbor strain live attenuated inﬂuenza vaccine in children and adultshttp://dx.doi.org/10.1016/j.trivac.2014.08.001
1879-4378/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer;
HAI, hemagglutination-inhibition; IIV, inactivated inﬂuenza vaccine; LAIV, live
attenuated inﬂuenza vaccine.
⇑ Corresponding author. Address: US Medical Affairs, AstraZeneca, One MedIm-
mune Way, Gaithersburg, MD 20878, United States. Tel.: +1 (415) 819 7666; fax: +1
(650) 603 3396.
E-mail addresses: coelinghk@medimmune.com (K.L. Coelingh), wilson.wu.
xionghua@gmail.com (X.W. Wu), malloryr@medimmune.com (R.M. Mallory),
ambrosec@medimmune.com (C.S. Ambrose).
1 Former employee of MedImmune, Gaithersburg, MD, United States.Kathleen L. Coelingh a,⇑, Xionghua W. Wu b,1, Raburn M. Mallory b, Christopher S. Ambrose a
aAstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, United States
bMedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States
a r t i c l e i n f oArticle history:
Received 12 June 2014
Revised 29 July 2014
Accepted 2 August 2014
Keywords:
Live attenuated inﬂuenza vaccine
LAIV
Serum HAI responsea b s t r a c t
Serum hemagglutination-inhibition (HAI) antibodies have been associated with protection from
inﬂuenza infection. HAI antibody responses to live attenuated inﬂuenza vaccines (LAIVs) and their role
in protection are not fully elucidated. This study characterizes HAI titers for LAIV. Serum HAI data were
pooled from 40 LAIV clinical trials enrolling subjects aged 2–49 years. Using pre- and postvaccination
titers, geometric mean fold rises (GMFRs) and seroresponse rates (P4-fold rise) were determined by
age and baseline serostatus (seronegative 68, seropositive >8). Responses were generally evaluated after
2 doses for those 2–8 years of age and after 1 dose for those 9–49 years of age. Data were available for
6909 children and 3444 adults. A total of 20 different LAIV formulations were used, representing 6
H1N1 strains, 9 H3N2 strains, 7 B/Yamagata lineage strains and 2 B/Victoria lineage strains. GMFRs were
modest overall; GMFRs were higher in children versus adults and higher in baseline seronegatives versus
baseline seropositives. This difference was greatest among children, with GMFRs ranging from 2.2 to 5.9
among seronegative and 1.2–1.5 among seropositive children. HAI responses were modest overall, higher
in seronegative individuals (10.8–61.6%) relative to seropositive (1.9–17.0%), and higher in children
relative to adults. Postvaccination HAI titers were below those associated with protection for inactivated
inﬂuenza vaccines. The results suggest that LAIV-induced protection is mediated primarily by mucosal
antibody and T-cell immunity, although serum HAI has value as strain-speciﬁc marker of response to
vaccination, particularly among seronegative individuals.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction and 40 in adults after vaccination with IIV are associated with 50%Serum hemagglutination-inhibition (HAI) antibodies are a
conveniently measured biomarker of inﬂuenza immunity. The
response to injectable inactivated inﬂuenza vaccine (IIV) has been
traditionally evaluated by serum HAI antibody responses, which
have been correlated with protection for IIV. Although a speciﬁc
serum HAI titer associated with protection from inﬂuenza provided
by IIV has not been identiﬁed in prospectively designed studies [1],
some studies have suggested that serumHAI titers of 110 in childrenprotection from infection [2–4]. In contrast, for nasal live attenuated
inﬂuenza vaccine (LAIV,MedImmune,Gaithersburg,MD), the serum
antibody HAI response and its relationship to protection from infec-
tion are less well characterized: although high rates of seroconver-
sion in serum HAI assays after vaccination with LAIV have been
associated with high efﬁcacy, high efﬁcacy has also been observed
with low rates of seroconversion [5]. The present study character-
izes the serum HAI antibody responses after LAIV vaccination using
data frommultiple studies in children and adults and examines fac-
tors associated with higher and lower response rates.2. Material and Methods
Serum HAI data were pooled from clinical studies in which
106.5–107.5 median tissue culture infectious doses or ﬂuorescent
focus forming units of the Ann Arbor strain LAIV (trivalent or
quadrivalent formulations of LAIV) was administered to
participants aged 2–49 years. Data from subjects aged <2 and
Fig. 1. Serum HAI antibody response rates after vaccination of children or adults
with LAIV. HAI = hemagglutination inhibition; LAIV = live attenuated inﬂuenza
vaccine.
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monovalent pandemic H1N1 vaccine were excluded from analysis.
Individual study participants or their parent/legal representative
gave written informed consent in all studies. Individual studies
were conducted in accordance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki).
Standardized serum HAI antibody assays were conducted as
previously described [6]. Brieﬂy, 2-fold dilutions of antiserum (2
replicates of each sample for the quadrivalent LAIV studies) were
incubated with 4 hemagglutinating units of inﬂuenza test viruses,
followed by addition of erythrocytes from a species previously
determined to be most sensitive to detect hemagglutination with
a given test virus. Serum antibody titers were the reciprocal of the
endpoint dilution of serum that inhibited hemagglutination by test
viruses. Test viruses used were wild-type inﬂuenza viruses corre-
sponding to the LAIV vaccine strains administered in clinical studies.
Pre- and postvaccination serum HAI antibody titers were used
to calculate geometric mean HAI titers (GMTs), geometric mean
fold rises (GMFRs) in serum HAI antibody titers, and seroresponse
rates (proportion of participants with a 4-fold or greater rise in
serum HAI antibody titer). GMFR was calculated as the geometric
mean of postvaccination serum HAI fold-rise from prevaccination
(ratio of postvaccination/prevaccination) of each subject. Pooled
GMTs, GMFRs, seroresponse rates and 95% conﬁdence intervals
were presented by vaccine type/subtype/lineage (i.e., A/H1N1,
A/H3N2, B/Yamagata, B/Victoria), participant age and baseline
serostatus. Seronegative baseline status was deﬁned as a prevacci-
nation antibody titer of 68; seropositive status was deﬁned as a
prevaccination antibody titer of >8. Postvaccination serum HAI
antibody responses were generally evaluated after 2 doses of LAIV
for children aged 2–8 years and 1 dose for individuals aged
9–49 years. Multivariate analyses were conducted to evaluate
associations of serum HAI titer, GMFR and seroresponse with age
(2–8, 9–17 and 18–49 years), gender, and baseline serostatus
(seronegative vs. seropositive).
3. Results
Forty studies of seasonal LAIV contributed available serum HAI
data for 6909 children (5555 children aged 2–8 years; 1354Table 1
Pooled geometric mean fold rise in serum HAI antibody titer and postvaccination geomet
Age, year Geometric mean fold rise in serum HAI antibody titer (95% conﬁdence in
Vaccine type/subtype
H1N1 H3N2
Seronegative Seropositive Seronegative Seropositive
2–8 n = 3347 n = 2113 n = 1858 n = 3538
3.7 (3.5, 3.8) 1.2 (1.1, 1.2) 5.9 (5.4, 6.3) 1.2 (1.1, 1.2)
9–17 n = 728 n = 626 n = 202 n = 1031
4.3 (3.8, 4.7) 1.3 (1.2, 1.4) 2.5 (2.1, 3.0) 1.3 (1.2, 1.3)
18–49 n = 2386 n = 1058 n = 1906 n = 1312
1.4 (1.3, 1.4) 1.0 (1.0, 1.0) 1.4 (1.3, 1.4) 1.1 (1.0, 1.1)
Age, year Postvaccination geometric mean HAI antibody titer (95% conﬁdence inte
Vaccine type/subtype
H1N1 H3N2
Seronegative Seropositive Seronegative Seropositive
2–8 n = 3347 n = 2113 n = 1858 n = 3538
8.7 (8.3, 9.0) 52.3 (50.0, 54.7) 14.8 (13.8, 15.9) 88.0 (84.8, 91.
9–17 n = 728 n = 626 n = 202 n = 1031
13.1 (11.8, 14.5) 67.8 (62.3, 73.7) 9.6 (7.9, 11.8) 121 (113, 128
18–49 n = 2386 n = 1058 n = 1906 n = 1312
3.7 (3.5, 3.8) 39.8 (37.3, 42.4) 4.0 (3.8, 4.1) 46.8 (44.1, 49.
HAI = hemagglutination inhibition, LAIV = live attenuated inﬂuenza vaccine.children aged 9–17 years) and 3444 adults aged 18–49 years. The
studies were conducted during 14 inﬂuenza seasons from 1995
to 1996 through 2009–2010, excluding 2003–2004. Trivalent and
quadrivalent LAIV vaccines administered were formulated to con-
tain attenuated LAIV strains recommended by the World Health
Organization for the inﬂuenza season in which the study was con-
ducted. In all, 20 different LAIV formulations were used, represent-
ing 6 H1N1 strains, 9 H3N2 strains, 7 B/Yamagata lineage strains
and 2 B/Victoria lineage strains. Pooled HAI data are presented
for GMFR and postvaccination GMT in Table 1, and as serum
antibody response rates in Fig. 1 GMTs after vaccination were sub-
stantially higher in baseline seropositive subjects versus baseline
seronegative subjects for the three age groups analyzed (Table 1).
For example, pooled GMTs to H1N1 strains were 8.7, 13.1 and
3.7, for seronegative subjects aged 2–8, 9–17 years and 18–49
years, respectively, and 52.3, 67.8 and 39.8 for seropositive sub-
jects aged 2–8, 9–17 and 18–49 years, respectively. In general,
GMTs achieved by children were higher than GMTs achieved by
adults for baseline seronegative and seropositive subjects.
Pooled GMFRs were modest overall. When analyzed by baseline
serostatus, GMFRs were higher in children versus adults and higher
in baseline seronegative subjects versus baseline seropositiveric mean titers after vaccination of children or adults with LAIV.
terval)
B/Yamagata lineage B/Victoria lineage
Seronegative Seropositive Seronegative Seropositive
n = 3099 n = 1727 n = 1275 n = 904
4.4 (4.2, 4.7) 1.4 (1.3, 1.4) 4.7 (4.4, 5.0) 1.5 (1.5, 1.6)
n = 409 n = 537 n = 382 n = 405
2.4 (2.2, 2.7) 1.2 (1.1, 1.3) 2.2 (2.0, 2.4) 1.2 (1.1, 1.2)
n = 521 n = 2197 n = 878 n = 1980
2.1 (1.9, 2.2) 1.1 (1.1, 1.2) 1.8 (1.7, 1.9) 1.1 (1.1, 1.1)
rval)
B/Yamagata lineage B/Victoria lineage
Seronegative Seropositive Seronegative Seropositive
n = 3099 n = 1727 n = 1275 n = 904
3) 11.6 (11.1, 12.2) 39.0 (37.2, 40.9) 13.3 (12.4, 14.3) 65.8 (61.7, 70.3)
n = 409 n = 537 n = 382 n = 405
.9) 7.8 (7.1, 8.7) 69.2 (63.1, 75.9) 7.5 (6.7, 8.3) 51.3 (46.7, 56.3)
n = 521 n = 2197 n = 878 1980
6) 9.2 (8.4, 10.0) 60.5 (57.8, 63.4) 8.3 (7.7, 8.8) 44.6 (42.8, 46.5)
152 K.L. Coelingh et al. / Trials in Vaccinology 3 (2014) 150–153subjects (Table 1). This difference was greatest among children;
GMFRs ranged from 2.2 to 5.9 among seronegative children versus
1.4–2.1 among seronegative adults; GMFRs ranged from 1.2 to 1.5
among seropositive children versus 1.0–1.1 among seropositive
adults. Overall, each of the three strains in trivalent LAIV was
immunogenic based on postvaccination GMFRs in serum HAI anti-
body titers, although responses were, in some cases, not detected
in seropositive adults. Overall, no type/subtype was consistently
more immunogenic by postvaccination GMT or GMFR. As expected,
postvaccination GMTs were substantially higher in baseline sero-
positive subjects versus baseline seronegative subjects (Table 1).
In seronegative subjects, pooled postvaccination GMTs were <15,
regardless of age.
Pooled HAI seroresponse rates (proportion of LAIV recipients
with a P4-fold increase in serum HAI titer) were also generally
modest (Fig. 1). Response rates among children and adults
were consistently higher among participants who were seronega-
tive before vaccination versus those who were seropositive
before vaccination. Seroresponse rates were consistently higher in
children versus adults, and generally higher in younger versus older
children. In younger children, all vaccine strains induced compara-
ble seroresponse rates, whereas in older children H1N1 strains, and,
in adults, B strains, induced higher seroresponse rates.
As reﬂected in Table 1 and Fig. 1, the multivariate analyses indi-
cated that young age and baseline seronegativity are statistically
signiﬁcant independent predictors of higher GMFRs and serore-
sponse rates (P < 0.0001). Adjusting for effect of baseline serosta-
tus, subject age of 18–49 years was associated with a fold-rise in
HAI titer that was 47–68% of the rise observed with age 2–8 years.
Adjusting for effect of age, baseline seronegativity was associated
with GMFRs that were 2.16–2.9-fold higher than those observed
with baseline seropositivity.4. Discussion
To characterize the serum HAI antibody response to LAIV, we
analyzed pooled data from 40 clinical studies of seasonal LAIV that
encompassed 14 inﬂuenza seasons and utilized 20 different LAIV
formulations representing a broad range of vaccine strains to
provide the most comprehensive summary of serum HAI responses
of children and adults to LAIV.
Each of the vaccine strain components in LAIV was immuno-
genic in children and adults. Generally, the serum HAI GMT
achieved, response rate and GMFR in antibody level following vac-
cination with LAIV were modest, and vaccine-induced responses
were higher with younger age and baseline seronegativity. The
most robust responses were observed among children, with sero-
negative children producing a greater response than seropositive
children.
These results suggest that the serum HAI response to LAIV var-
ies with age and prior exposure to inﬂuenza. Compared with indi-
viduals with no detectable serum HAI antibodies, antibody titers of
at least 110 or 40 have been associated with 50% reduction in risk
of inﬂuenza infection or inﬂuenza disease for children and adults,
respectively [2–4]. Because of this association, the protective
response to IIV administered by intramuscular or intradermal
injection has been traditionally assessed on the basis of the serum
HAI antibody response among healthy younger and older adults
using speciﬁc criteria [7]. Requirements for annual re-licensure of
IIV in the European Union have included assessment of the serore-
sponse to vaccine strains; criteria for a satisfactory immune
response among younger adults aged 18–60 years include a 40%
seroresponse rate or a 2.5 GMFR in antibody titer to vaccine [8].
Although uncertainty exists regarding the ability of serum HAI
antibody responses to identify poorly immunogenic IIV or toaccurately assess immunogenicity of IIV in children, induction of
high levels of serum HAI antibodies is generally accepted as the
mechanism of action and correlate of protection for IIV [7].
For newer inﬂuenza vaccines such as LAIV, which comprises live
attenuated vaccine strains that are administered to the nasal
mucosa, an immune correlate for clinical protection has not been
established. However, high LAIV efﬁcacy has been observed in
studies reporting low and high rates of HAI antibody seroresponse
[5,9]. Similarly, protection of LAIV-vaccinated adults against exper-
imental wild-type inﬂuenza virus challenge in the absence of a sig-
niﬁcant serum HAI antibody response has been documented [10].
It appears, therefore, that other immune mechanisms must be
the primary mediators of protection conferred by LAIV.
A variety of immune responses to LAIV have been demon-
strated. LAIV induces mucosal IgA antibody responses in children
and higher levels of inﬂuenza-speciﬁc IgA are associated with pro-
tection from inﬂuenza illness [11,12]. LAIV has also been shown to
induce substantial cellular immune responses in young children;
higher cellular responses were associated with protection [13].
CD4+, CD8+ and cd+ T cells have been shown to be induced by LAIV
in young children, older children and adults [14,15]. Innate
immune responses may contribute to protection against inﬂuenza
illness in the weeks immediately following vaccination [16]. The
diverse types of immune responses induced by LAIV resemble
the response to natural inﬂuenza infection [17].
Despite the limitations of serum HAI antibody responses to doc-
ument protective immunity provided by LAIV, such responses have
utility as a strain-speciﬁc biomarker for comparing the immune
response to different formulations of LAIV, particularly among
seronegative individuals. Therefore, the most appropriate use of
serum HAI antibody responses to LAIV is to enable assessment of
formulation bridging, manufacturing and lot consistency, and con-
comitant administration of LAIV with other live virus vaccines.
Given that LAIV can induce protective immunity in the absence
of a meaningful HAI response, serum HAI antibody responses to
LAIV are not valuable as a marker of vaccine efﬁcacy.
The present study was limited because it did not assess the rela-
tionship of serum HAI responses to protection provided by LAIV.
The strength of the study was its comprehensive nature, including
a large number of vaccine recipients who were evaluated over
many inﬂuenza seasons following vaccination with diverse LAIV
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